James P Wick1, Tanvir C Turin2, Peter D Faris1, Jennifer M MacRae1, Robert G Weaver3, Marcello Tonelli3, Braden J Manns4, Brenda R Hemmelgarn5. 1. Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Canada. 2. Department of Family Medicine, Cumming School of Medicine, University of Calgary, Calgary, Canada. 3. Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, Canada. 4. Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Canada; Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, Canada. 5. Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Canada; Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, Canada. Electronic address: brenda.hemmelgarn@albertahealthservices.ca.
Abstract
BACKGROUND: Information on an individual's risk for death following dialysis therapy initiation may inform the decision to initiate maintenance dialysis for older adults. We derived and validated a clinical risk prediction tool for all-cause mortality among older adults during the first 6 months of maintenance dialysis treatment. STUDY DESIGN: Prediction model using retrospective administrative and clinical data. SETTING & PARTICIPANTS: We linked administrative and clinical data to define a cohort of 2,199 older adults (age ≥ 65 years) in Alberta, Canada, who initiated maintenance dialysis therapy (excluding acute kidney injury) in May 2003 to March 2012. CANDIDATE PREDICTORS: Demographics, laboratory data, comorbid conditions, and measures of health system use. OUTCOMES: All-cause mortality within 6 months of dialysis therapy initiation. ANALYTICAL APPROACH: Predicted mortality by logistic regression with 10-fold cross-validation. RESULTS: 375 (17.1%) older adults died within 6 months. We developed a 19-point risk score for 6-month mortality that included age 80 years or older (2 points), glomerular filtration rate of 10 to 14.9mL/min/1.73m2 (1 point) or ≥15mL/min/1.73m2 (3 points), atrial fibrillation (2 points), lymphoma (5 points), congestive heart failure (2 points), hospitalization in the prior 6 months (2 points), and metastatic cancer (3 points). Model discrimination (C statistic = 0.72) and calibration (Hosmer-Lemeshow χ2=10.36; P=0.2) were reasonable. As examples, a score < 5 equated to <25% of individuals dying in 6 months, whereas a score > 12 predicted that more than half the individuals would die in the first 6 months. LIMITATIONS: The tool has not been externally validated; thus, generalizability cannot be assessed. CONCLUSIONS: We used readily available clinical information to derive and internally validate a 7-variable tool to predict early mortality among older adults after dialysis therapy initiation. Following successful external validation, the tool may be useful as a clinical decision tool to aid decision making for older adults with kidney failure.
BACKGROUND: Information on an individual's risk for death following dialysis therapy initiation may inform the decision to initiate maintenance dialysis for older adults. We derived and validated a clinical risk prediction tool for all-cause mortality among older adults during the first 6 months of maintenance dialysis treatment. STUDY DESIGN: Prediction model using retrospective administrative and clinical data. SETTING & PARTICIPANTS: We linked administrative and clinical data to define a cohort of 2,199 older adults (age ≥ 65 years) in Alberta, Canada, who initiated maintenance dialysis therapy (excluding acute kidney injury) in May 2003 to March 2012. CANDIDATE PREDICTORS: Demographics, laboratory data, comorbid conditions, and measures of health system use. OUTCOMES: All-cause mortality within 6 months of dialysis therapy initiation. ANALYTICAL APPROACH: Predicted mortality by logistic regression with 10-fold cross-validation. RESULTS: 375 (17.1%) older adults died within 6 months. We developed a 19-point risk score for 6-month mortality that included age 80 years or older (2 points), glomerular filtration rate of 10 to 14.9mL/min/1.73m2 (1 point) or ≥15mL/min/1.73m2 (3 points), atrial fibrillation (2 points), lymphoma (5 points), congestive heart failure (2 points), hospitalization in the prior 6 months (2 points), and metastatic cancer (3 points). Model discrimination (C statistic = 0.72) and calibration (Hosmer-Lemeshow χ2=10.36; P=0.2) were reasonable. As examples, a score < 5 equated to <25% of individuals dying in 6 months, whereas a score > 12 predicted that more than half the individuals would die in the first 6 months. LIMITATIONS: The tool has not been externally validated; thus, generalizability cannot be assessed. CONCLUSIONS: We used readily available clinical information to derive and internally validate a 7-variable tool to predict early mortality among older adults after dialysis therapy initiation. Following successful external validation, the tool may be useful as a clinical decision tool to aid decision making for older adults with kidney failure.
Authors: Ryan T Anderson; Hailey Cleek; Atieh S Pajouhi; M Fernanda Bellolio; Ananya Mayukha; Allyson Hart; LaTonya J Hickson; Molly A Feely; Michael E Wilson; Ryan M Giddings Connolly; Patricia J Erwin; Abdul M Majzoub; Navdeep Tangri; Bjorg Thorsteinsdottir Journal: Clin J Am Soc Nephrol Date: 2019-07-30 Impact factor: 8.237
Authors: Ismay N van Loon; Namiko A Goto; Franciscus T J Boereboom; Michiel L Bots; Ellen K Hoogeveen; Laila Gamadia; E F H van Bommel; P J G van de Ven; Caroline E Douma; H H Vincent; Yvonne C Schrama; Joy Lips; Machiel A Siezenga; Alferso C Abrahams; Marianne C Verhaar; Marije E Hamaker Journal: Nephron Date: 2019-08-13 Impact factor: 2.847
Authors: Namiko A Goto; Ismay N van Loon; Franciscus T J Boereboom; Marielle H Emmelot-Vonk; Hanna C Willems; Michiel L Bots; Laila E Gamadia; Eric F H van Bommel; Peter J G Van de Ven; Caroline E Douma; Hieronymus H Vincent; Yvonne C Schrama; Joy Lips; Ellen K Hoogeveen; Machiel A Siezenga; Alferso C Abrahams; Marianne C Verhaar; Marije E Hamaker Journal: Clin J Am Soc Nephrol Date: 2019-06-27 Impact factor: 8.237
Authors: Rasheeda K Hall; Sarah Morton; Jonathan Wilson; Patti L Ephraim; L Ebony Boulware; Wendy L St Peter; Cathleen Colón-Emeric; Jane Pendergast; Julia J Scialla Journal: BMC Nephrol Date: 2021-06-19 Impact factor: 2.585
Authors: Victoria Garcia-Montemayor; Alejandro Martin-Malo; Carlo Barbieri; Francesco Bellocchio; Sagrario Soriano; Victoria Pendon-Ruiz de Mier; Ignacio R Molina; Pedro Aljama; Mariano Rodriguez Journal: Clin Kidney J Date: 2020-08-11